NVS analyst estimates
Novartis (NVS) analyst ratings, the average price target and its range, and every firm's latest call.
NVS analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 28, 2026 | Morgan Stanley | Novartis price target raised to $163 from $156 at Morgan Stanley | $163.00 |
| Oct 6, 2026 | Morgan Stanley | Novartis price target lowered to $156 from $170 at Morgan Stanley | $156.00 |
| Sep 10, 2026 | HSBC | HSBC upgrades Novartis to Hold with negative catalysts played out | $136.00 |
| Mar 26, 2026 | Morgan Stanley | Novartis price target raised to $170 from $143 at Morgan Stanley | $170.00 |
| Dec 10, 2025 | HSBC | Novartis price target raised to $112 from $106 at HSBC | $112.00 |
| Dec 3, 2025 | Morgan Stanley | Novartis price target raised to $143 from $136 at Morgan Stanley | $143.00 |
| Oct 29, 2025 | CFRA | Novartis (NVS) PT Raised to $126 at CFRA | $126.00 |
| Oct 30, 2024 | BMO Capital | Novartis (NVS) PT Raised to $120 at BMO Capital | $120.00 |
| Sep 5, 2024 | Goldman Sachs | Novartis downgraded to Neutral from Buy at Goldman Sachs | $121.00 |
| Jul 19, 2024 | BMO Capital | Novartis (NVS) PT Raised to $118 at BMO Capital | $118.00 |
| Apr 23, 2024 | CFRA | Novartis (NVS) PT Raised to $108 at CFRA | $108.00 |
- 13 firms rate NVS: 5 buy, 7 hold, 1 sell.
- The average price target is $149.50 from 2 analysts, from $136.00 to $163.00.
Updated 2026-11-02 18:26 UTC